We are delighted to invite you to the AbbVie-sponsored symposium “The Expanding Role of Precision Medicine with Antibody Drug Conjugates in NSCLC” during this year’s hybrid IASLC 2023 World Conference on Lung Cancer. Multidisciplinary experts in thoracic oncology and pathology will discuss the expanding precision medicine treatment paradigm with antibody drug conjugates in NSCLC.

Topics

• Current NSCLC treatment landscape and expanding treatment options with antibody drug conjugates
• Getting to know ADCs: Differentiating composition and mechanisms of action and latest evidence of ongoing trials with antibody drug conjugates
• Integrating biomarker expression testing and patient selection into clinical practice: Practicalities, challenges, and future directions

For Healthcare Professionals only.

This program was approved by the IASLC 2023 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2023 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program. Presentations contain information about investigational molecules that are not approved by regulatory authorities (alone or in combination) and that are being studied for unapproved uses. Safety and efficacy have not been established.

cMET-AA-00066-E, v1; Approval date: August 2023

Speakers

Ross Camidge, MD, PhD
University of Colorado, Anschutz Medical Campus
Director of the Thoracic Oncology Clinical and Clinical Research Program
Aurora, CO

David Planchard, MD, PhD
Gustave Roussy Institute of Oncology
Head of Thoracic Pathology Committee
Villejuif, France

Umberto Malapelle, PhD
University of Naples
Assistant Professor, Researcher in Anatomic Pathology
Naples, Italy